Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS 46 Cyclically Adjusted PS Ratio is 16.17 as of Jul. 14, 2026, which is 709% above its 10-year median of 2.00. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 539 Biotechnology companies, BLS Pharmaceuticals ranks worse than 76.44% on this metric.
The historical rank and industry rank for BLS Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
ASX:BLS'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.35 Med: 2 Max: 17.5
Current: 16.04
During the past 13 years, BLS Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 17.50. The lowest was 0.35. And the median was 2.00.
ASX:BLS's Cyclically Adjusted PS Ratio is ranked worse than 76.44% of 539
companies
in the Biotechnology industry
Industry Median: 5.83
vs ASX:BLS: 16.04
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
BLS Pharmaceuticals's adjusted revenue per share data of for the fiscal year that ended in Jun25 was A$0.122. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is A$0.06 for the trailing ten years ended in Jun25.
Shiller PE for Stocks: The True Measure of Stock Valuation
BLS Pharmaceuticals (ASX:BLS) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
BLS Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms
BLS Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals Cyclically Adjusted PS Ratio Chart
ASX:BLS vs KHC, GIS: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, BLS Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
BLS Pharmaceuticals Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
BLS Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 16.17 mean?
BLS Pharmaceuticals (ASX:BLS) has a Cyclically Adjusted PS Ratio of 16.17 as of Jul. 14, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on BLS Pharmaceuticals and its competitors. This is 709% above median its historical median of 2.00. Over the past decade, BLS Pharmaceuticals' Cyclically Adjusted PS Ratio has ranged from 0.35 to 17.50. According to the industry distribution chart, BLS Pharmaceuticals ranks #412 out of 539 companies in the Biotechnology industry, placing it in the top 76.4%.
Is BLS Pharmaceuticals' Cyclically Adjusted PS Ratio too high?
BLS Pharmaceuticals' current Cyclically Adjusted PS Ratio of 16.17 is 709% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 17.50. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.83. BLS Pharmaceuticals' value of 16.17 is 177.4% above this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #412 out of 539 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Cyclically Adjusted PS Ratio compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #412 out of 539 companies for Cyclically Adjusted PS Ratio. This places BLS Pharmaceuticals in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.83. BLS Pharmaceuticals' value of 16.17 is 177.4% above this benchmark. Historically, BLS Pharmaceuticals' own Cyclically Adjusted PS Ratio has ranged from 0.35 to 17.50 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 5.83, BLS Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.83, based on 539 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current Cyclically Adjusted PS Ratio of 16.17 is 177.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Cyclically Adjusted PS Ratio is 16.17, which is 709% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 16.17, which is 709% above median its 10-year median of 2.00 and 177.4% above the Biotechnology industry median of 5.83. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Cyclically Adjusted PS Ratio is 16.17 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
Cyclically Adjusted PS Ratio: 16.17 (709% above median its 10-year median of 2.00)
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
Industry Position: 177.4% above the Biotechnology median (#412 of 539)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
